When Oxygen Isn't Enough

A Critical Appraisal of the 2026 ATS - NIV Clinical Practice Guidelines

“The best respiratory support isn't the newest device. It's the one that best matches the patient's physiology”

Summarised By -
Dr Arihant Jain, MD | lifeonthefrontline.com
Instagram: @humans.of.em
X | Linkedin | ORCID
—————————————————————
It Started Like Every Other Night Shift

It was 2:17 a.m.

The emergency call from triage was brief.

“Sixty-eight-year-old male. Severe breathlessness. Oxygen saturation 84%.”

Within minutes, he was wheeled into the resuscitation bay. He looked frightened.

His respiratory rate was nearly 40 breaths per minute. Every breath was laboured. The accessory muscles in his neck were contracting with each inspiration, and despite receiving oxygen through a non-rebreather mask at 15 litres per minute, his oxygen saturation refused to climb beyond 86%.

The chest radiograph showed bilateral infiltrates. The arterial blood gas confirmed severe hypoxaemia. There was no significant hypercapnia.

The respiratory therapist looked at me.

“Should we start High-Flow Nasal Cannula?”

Across the room another physician asked,

“What about non-invasive ventilation?”

Meanwhile, someone quietly prepared the intubation drugs.

Three experienced clinicians.
Three different answers.
One patient.

Ten years ago, all three decisions could probably have been justified.

Today, the conversation is different—not because we have better machines, but because we have better evidence.

The recently published 2026 American Thoracic Society (ATS) Clinical Practice Guideline on Non-Invasive Respiratory Support for Adult Patients with Acute Respiratory Failure brings together nearly two decades of research to answer one simple question:

Which respiratory support should we choose, and more importantly, why?

Interestingly, the guideline is not organised around devices like HFNC, NIV or CPAP. Instead, it focuses on clinical syndromes—acute hypoxaemic respiratory failure, acute hypercapnic respiratory failure, pre-intubation support and post-extubation care. That shift may seem subtle, but it fundamentally changes how we think about respiratory support.

Stop Choosing Devices.
Start Understanding Physiology.

One of the biggest lessons from this guideline is that respiratory failure is not a single disease. Our patient with pneumonia is hypoxaemic because oxygen cannot effectively cross injured alveoli into the bloodstream.

A patient with COPD, on the other hand, often fails because they cannot ventilate adequately. Carbon dioxide accumulates, respiratory muscles fatigue and the work of breathing becomes unsustainable.

Both patients may look equally distressed. Both may have similar oxygen saturations. Yet they need completely different treatments. The question therefore is no longer,

“Which machine should I use?”

Instead, it becomes,

“What physiological problem am I trying to solve?”

That single question explains almost every recommendation in the ATS guideline.

How Are Guidelines Actually Made?

Most of us skip straight to the recommendations.

Strong recommendation.
Conditional recommendation.
Use.
Don’t use.
Move on.

But recommendations don’t appear overnight.

The ATS panel reviewed the available evidence using systematic reviews, network meta-analyses and the GRADE Evidence-to-Decision framework. Rather than asking whether a single trial was “positive” or “negative,” they looked at the totality of evidence, considering benefits, harms, certainty of evidence, patient values, feasibility and resource implications before making each recommendation.

This explains something many clinicians find confusing.

A strong recommendation does not necessarily mean there is overwhelming evidence for mortality benefit.

Instead, it means the panel is confident that, for most patients, the overall benefits outweigh the harms.

That distinction becomes very important as we return to our patient.

The Story of High-Flow Nasal Cannula

Twenty years ago, patients like ours had very few options. They usually received conventional oxygen therapy until one of two things happened. Either they improved or they deteriorated enough to require intubation.

Conventional oxygen therapy has obvious limitations. Patients with severe respiratory distress often generate inspiratory flow rates much higher than the oxygen delivered through a face mask. As a result, room air becomes entrained, reducing the effective oxygen concentration reaching the lungs.

Clinicians therefore began looking for better alternatives.

High-flow nasal cannula (HFNC) appeared promising because it could deliver heated, humidified oxygen at much higher flow rates while maintaining a more consistent inspired oxygen concentration. Physiological studies also suggested that HFNC reduced anatomical dead space, generated a small amount of positive airway pressure and decreased the work of breathing.

The physiology made sense.

But physiology alone is never enough.

Clinical trials had to prove that these benefits translated into better patient outcomes.

The Trial That Changed the Conversation

A major turning point came with the FLORALI trial by Frat and colleagues (2015).

The investigators compared HFNC with conventional oxygen therapy and non-invasive ventilation in patients with acute hypoxaemic respiratory failure.

Although the primary outcome did not show a statistically significant reduction in intubation across the entire study population, HFNC demonstrated encouraging results, particularly among patients with more severe hypoxaemia. Mortality also appeared lower in some groups.

Perhaps more importantly, patients tolerated HFNC remarkably well. Suddenly, clinicians began asking a new question. Could HFNC become the first-line treatment for hypoxaemic respiratory failure?

FLORALI did not answer that question completely. But it changed the direction of research for the next decade.

Then Came COVID-19

The COVID-19 pandemic accelerated respiratory research more than anyone could have imagined. Hospitals across the world faced thousands of patients with severe viral pneumonia. Researchers rapidly compared HFNC, CPAP and non-invasive ventilation in randomised clinical trials.

Studies such as HENIVOT (Grieco et al., 2021) and RECOVERY-RS (Perkins et al., 2022) added valuable evidence, although they did not always reach identical conclusions. Some trials suggested benefits with CPAP. Others supported HFNC.

Some remained inconclusive.

Instead of providing one clear answer, the growing evidence highlighted an important reality:

No single trial should determine clinical practice.

This is exactly why the ATS panel performed a comprehensive evidence synthesis rather than relying on individual studies.

So Why Does ATS Recommend HFNC?

This is perhaps the most important question.

After reviewing 39 randomised controlled trials, the ATS panel concluded that HFNC should be preferred over conventional oxygen therapy for adults with de novo acute hypoxaemic respiratory failure, issuing a strong recommendation.

At first glance, that may seem surprising. The evidence for reducing mortality is not definitive. So why such a strong recommendation?

Because mortality is not the only outcome that matters.

Across multiple studies, HFNC consistently reduced the need for invasive mechanical ventilation, improved patient comfort and was generally well tolerated. Patients could communicate, eat, drink and clear secretions more easily than those receiving tightly fitting masks.

Importantly, HFNC also carried relatively few serious adverse effects.

When the ATS panel weighed all these outcomes together, the balance clearly favoured HFNC. This is an important reminder that evidence-based medicine is about more than a single p-value.

Why Not Simply Use NIV?

Many clinicians naturally ask another question. If non-invasive ventilation provides positive pressure, shouldn’t it work even better?

The answer is more nuanced.

NIV certainly has physiological advantages. It can reduce the work of breathing and improve gas exchange. However, it also comes with important drawbacks.

Tight-fitting masks are often uncomfortable.

Air leaks are common.

Pressure injuries may develop.

Patients frequently struggle to tolerate prolonged treatment.

Perhaps the greatest concern is delayed recognition of treatment failure. Continuing NIV in a patient who is steadily worsening may postpone intubation, potentially worsening outcomes. The ATS panel also discussed concerns that excessive spontaneous tidal volumes during NIV could contribute to further lung injury in some patients.

For these reasons, the guideline makes only a conditional recommendation for NIV in de novo hypoxaemic respiratory failure, while strongly recommending HFNC as the preferred initial strategy.

Back to Our Patient

The high-flow nasal cannula is connected.

Warm, humidified oxygen begins flowing.

Within minutes, his breathing slows.

His oxygen saturation climbs into the low 90s.

He is still critically ill.

But he is more comfortable.

More importantly, we have bought ourselves time to reassess, investigate and decide whether he truly needs intubation.

That is perhaps the biggest lesson from this part of the ATS guideline.

HFNC is not simply a better oxygen mask. It is a form of respiratory support that allows us to treat hypoxaemic respiratory failure while reducing the need for invasive ventilation in many patients. But as we leave this patient and walk toward the next bed, we encounter a completely different problem.

A woman with severe COPD.

She is not hypoxaemic because her lungs cannot absorb oxygen. She is hypercapnic because her lungs cannot eliminate carbon dioxide.

The same device that helped our first patient may not be the best choice for her.

Because in acute care, the right treatment is determined not by the machine, but by the physiology.

A Different Patient. A Different Problem.

As we finished stabilising our patient with severe pneumonia, another call came from the acute care unit. A 72-year-old woman with severe chronic obstructive pulmonary disease (COPD) had become progressively drowsy over the past few hours.

Unlike the previous patient, she was not gasping for breath.

She looked tired.

Every breath was shallow.

Her respiratory rate was only 24 breaths per minute, but her accessory muscles had clearly been working for hours.

The arterial blood gas told the real story.

pH: 7.22

PaCO₂: 78 mmHg

PaO₂: 64 mmHg

This wasn’t simply hypoxaemia.

This was ventilatory failure.

The resident, fresh from treating the previous patient, asked confidently,

“Should we start High-Flow Nasal Cannula?”

The consultant smiled.

“Different physiology, Different treatment.”

That single sentence probably summarises the entire ATS guideline better than any recommendation table.

When Carbon Dioxide Is the Problem

The patient with pneumonia struggled because oxygen couldn’t cross injured alveoli. The patient with COPD struggles because she cannot remove carbon dioxide. Years of airway obstruction have increased airway resistance, caused dynamic hyperinflation and placed enormous demands on already fatigued respiratory muscles.

Each breath requires tremendous effort. Eventually those muscles tire. Ventilation falls. Carbon dioxide rises. Acidosis develops. Unlike hypoxaemic respiratory failure, simply increasing oxygen does not solve the problem.

The patient needs assistance with ventilation, not just oxygenation.

That distinction explains why the ATS guideline makes very different recommendations for acute hypercapnic respiratory failure.

The Trial That Changed Everything

If there is one landmark trial that transformed acute respiratory care, it is the study by Brochard et al. (1995). Before this study, many patients with severe COPD exacerbations progressed directly to invasive mechanical ventilation.

Brochard and colleagues demonstrated that non-invasive ventilation (NIV) significantly reduced the need for intubation and improved clinical outcomes in carefully selected patients. For the first time, clinicians realised they could support ventilation without placing an endotracheal tube.

Several years later, Plant et al. (2000) showed that NIV could also be successfully delivered outside the intensive care unit, making this therapy available to far more patients. Together, these studies changed clinical practice worldwide.

Unlike many newer respiratory interventions, the evidence supporting NIV in COPD has remained remarkably consistent over time.

Does High-Flow Change the Story?

Over the past decade, enthusiasm for HFNC naturally extended to patients with COPD. After all, HFNC improves comfort, reduces anatomical dead space and decreases the work of breathing.

Could it replace NIV?

Several recent randomised trials explored this possibility. Some suggested that HFNC produced similar improvements in carefully selected patients with mild hypercapnia. Others showed better patient comfort and tolerance. These findings generated considerable excitement.

But the ATS panel looked beyond individual studies.

They examined the entire body of evidence. Most of these trials enrolled patients with relatively mild respiratory acidosis. Many allowed patients to cross over from HFNC to NIV when deterioration occurred. Very few included patients with severe hypercapnic respiratory failure. As a result, the evidence remained less certain than it initially appeared.

Why NIV Still Comes First

After reviewing 43 randomised controlled trials, the ATS panel concluded that NIV remains the preferred initial treatment for adults with acute hypercapnic respiratory failure, issuing a strong recommendation.

The reasoning is straightforward. NIV does something HFNC cannot reliably achieve. It actively assists ventilation. Inspiratory pressure support unloads fatigued respiratory muscles. Minute ventilation improves. Carbon dioxide falls. Acidosis begins to correct.

HFNC certainly has physiological benefits, but the available evidence does not yet demonstrate that it consistently replaces NIV in patients with clinically significant ventilatory failure.

That is why the ATS guideline takes a cautious approach.

HFNC may be considered in selected patients with mild respiratory acidosis, particularly when NIV is poorly tolerated, provided clinicians monitor the patient closely and are prepared to escalate treatment rapidly if deterioration occurs.

Once again, the recommendation reflects physiology.

Patients who cannot ventilate generally require ventilatory assistance.

Another Critical Moment: PreIntubation

Our first patient with pneumonia initially improved on HFNC. Six hours later, everything changed. His oxygen requirement continued to increase. He became increasingly confused. His respiratory muscles finally began to fail.

Now there was no debate.

He needed intubation. A new question emerged.

How should we oxygenate him before laryngoscopy?

For years, clinicians relied on conventional bag-mask ventilation. More recently, HFNC and NIV have both been proposed as superior preoxygenation strategies.

Randomised studies have shown benefits with both approaches in different clinical settings.

After reviewing the available evidence, the ATS guideline concludes that either HFNC or NIV is preferable to conventional oxygen therapy before intubation in acute hypoxemic respiratory failure, while recognising that current evidence is insufficient to recommend one clearly over the other.

Perhaps the most important message is that preoxygenation should not be an afterthought.

A patient with severe respiratory failure has very little physiological reserve.

Optimising oxygenation before induction may reduce life-threatening desaturation during airway management.

The Journey Doesn’t End After Extubation

Several days later, our patient improved. The infection resolved. Vasopressors were discontinued. He successfully completed a spontaneous breathing trial. Now another important decision awaited.

Should he receive conventional oxygen after extubation?

HFNC?

Or NIV?

Extubation is often viewed as the finish line. In reality, it is another high-risk transition. Some patients develop respiratory failure shortly after extubation and require re-intubation, an event associated with increased morbidity and mortality.

The ATS guideline therefore addresses respiratory support after extubation separately.

Rather than recommending the same strategy for every patient, the panel emphasises individual risk assessment.

Patients at higher risk of extubation failure may benefit from NIV, whereas HFNC represents an effective alternative in many others. Both strategies are favoured over conventional oxygen in appropriate clinical settings.

Once again, the message is remarkably consistent. Choose the therapy that matches the patient’s physiology and clinical risk.

What Makes This Guideline Different?

Every guideline tells us what to do. Good guidelines explain why. This ATS guideline succeeds because it avoids oversimplifying respiratory support. It does not claim that HFNC is universally superior. It does not suggest NIV is obsolete. Instead, it reminds us that every device has strengths, limitations and an appropriate clinical context.

Perhaps more importantly, it demonstrates how recommendations should be developed. The panel did not rely on a single influential study.

Instead, they systematically reviewed the available evidence, evaluated its certainty, balanced benefits against harms and considered patient values, feasibility and resource implications before issuing recommendations. For clinicians, this approach is just as valuable as the recommendations themselves.

Five Lessons I’ll Take Back to the Bedside

After reading the guideline, five practical lessons stand out.

1. Treat physiology before devices.

The question is never “HFNC or NIV?”

It is “What type of respiratory failure does this patient have?”

2. High-flow nasal cannula is no longer just an oxygen device.

It is a form of respiratory support that has become the preferred first-line therapy for many patients with de novo acute hypoxaemic respiratory failure.

3. NIV remains the cornerstone of acute hypercapnic respiratory failure.

Despite exciting research on HFNC, patients with significant ventilatory failure still benefit most from ventilatory assistance.

4. Strong recommendations are not based on mortality alone.

Comfort, avoidance of intubation, adverse events and patient preferences all matter.

5. Reassessment is more important than the initial device.

No form of respiratory support is successful if clinicians fail to recognise deterioration and escalate treatment when necessary.

Pulse Check

When I first started training, respiratory support often felt like choosing between machines. Today, I realise it is really about understanding physiology. The patient with pneumonia and the patient with COPD may arrive breathless, frightened and hypoxic. They may even occupy neighbouring beds. But their lungs are failing for completely different reasons.

The 2026 ATS guideline reminds us that evidence-based medicine is not about finding one device that works for everyone.

It is about recognising the physiological problem in front of us and choosing the therapy most likely to solve it. Technology will continue to evolve. New interfaces will emerge. Future trials may modify today’s recommendations.

But one principle is unlikely to change:

The best respiratory support is not the newest machine. It is the one that best matches the patient’s physiology, is supported by the strongest available evidence and is accompanied by continuous bedside reassessment.

That is the real lesson from twenty years of research—and perhaps the most important lesson for every acute care clinician.

Suggested Reading -
Goel A, Rochwerg B, Nava S, et al. Noninvasive respiratory support for adult patients with acute respiratory failure: An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2026;214(4):e30-e58. doi:10.1164/rccm.202607-1135ST